A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Inclusion Criteria:

- Age 18 to 75 years, inclusive, at the start of the run-in period

- AD diagnosed by the Hanifin/Rajka criteria and that has been present for at least 1
year at screening

- Moderate to severe AD as graded by the Rajka/Langeland criteria at screening

- History of inadequate response to a >/= 1 month (within the 3 months prior to the
screening visit) treatment regimen of at least daily TCS and regular emollient for
treatment of AD

- EASI score >/= 14 at screening

- IGA score >/= 3

- AD involvement of >/= 10% body surface area

- Pruritus Visual Analog Scale score >/= 3

Exclusion Criteria:

- Past and/or current use of any anti-IL-13 or anti-IL-4/IL-13 therapy, including
lebrikizumab

- Use of an investigational agent within 4 weeks prior to screening or within 5
half-lives of the investigational agent, whichever is longer

- Evidence of other skin conditions, including, but not limited to, T-cell lymphoma or
allergic contact dermatitis

- History of a severe allergic reaction or anaphylactic reaction to a biologic agent or
known hypersensitivity to any component of the lebrikizumab injection

- Use of any complementary, alternative, or homeopathic medicines including, but not
limited to, phytotherapies, traditional or non-traditional herbal medications,
essential fatty acids, or acupuncture within 7 days prior to the run-in period or
need for such medications during the study

- Evidence of other skin conditions; including, but not limited to, T-cell lymphoma or
allergic contact dermatitis

- Evidence of, or ongoing treatment (including topical antibiotics) for active skin
infection at screening

- Other recent infections meeting protocol criteria

- Active tuberculosis requiring treatment within the 12 months prior to Visit 1

- Evidence of acute or chronic hepatitis or known liver cirrhosis

- Known immunodeficiency, including HIV infection

- Use of a topical calcineurin inhibitor (TCI) at the time of screening, unless the
patient is willing to stop TCI use during the study (including the run-in period)
and, in the investigator's opinion, it is safe to do so

- Clinically significant abnormality on screening ECG or laboratory tests

- Known current malignancy or current evaluation for a potential malignancy, including
basal or squamous cell carcinoma of the skin or carcinoma in situ

- History of malignancy within 5 years prior to screening, except for appropriately
treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine
cancer